Chimeric Therapeutics (CHM) investor relations material

CHM CDH17 clinical program update

• Phase 1 trial of autologous CAR-T targeting CDH17 is ongoing at four major US sites, with IND cleared in Nov 2023 and fast track designation achieved in April 2024.

• Eight patients have been treated, with 10/10 successful GMP manufacturing runs and no safety issues or off-target effects observed.

• Tumor shrinkage up to 37% and stable disease have been observed in several patients, with one patient showing stable disease at 10 months.

• Dose level 1 is completed, dose level 2 recruitment is ongoing, and dose level 3 recruitment is underway.

• Phase 1 is nearing completion, with Phase 2 to begin without further FDA review; orphan drug designation is under review.

CHM CORE-NK clinical program update

• CHM CORE-NK is an off-the-shelf allogeneic NK cell therapy, manufactured from universal donors, with up to 200 doses per donor.

• Investigator-initiated trials at MD Anderson and Case Western are ongoing, with MD Anderson leading a frontline AML study combining CORE-NK with azacitidine and venetoclax.

• Seven patients treated in the frontline study, with four complete responses and one partial response; no safety issues observed.

• Dose escalation is complete, and first-line dosing is underway, aiming for up to 20 patients.

• Full data readout expected mid-next year, with ongoing updates planned.

Commercial and regulatory outlook

• Significant commercial interest in CDH17 asset due to large market size and unique CAR-T approach; multiple partnership discussions ongoing.

• Manufacturing capacity gaps at major pharma present opportunities for scaling.

• Regulatory path for CDH17 may allow for Phase 2 registration, following precedent in cell therapy approvals.

• Orphan drug designation for CDH17 is under review; no designation yet for CORE-NK.

• The global market size for target indications is estimated at $27.7B in 2024.